Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care
Other antidepressants
4 evidence topics · 4 sources
CANMAT guideline: agomelatine, imipramine, bupropion XL, vortioxetine, mirtazapine, and trazodone
“Other antidepressants: In two 12-week, double-blind RCTs, agomelatine was found to be more effective than placebo (Level 1)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In RCTs, imipramine was superior to placebo and as effective as benzodiazepines for the treatment of GAD (Level 1)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“However, because of side effects and potential toxicity in overdose, imipramine is recommended as a second-line option.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“While there are little data on bupropion XL (Level 2), in a 12-week RCT in patients with GAD it was as effective as escitalopram (a first-line option), supporting its use as a second-line option” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Results from two similar, eight-week, placebo-controlled RCTs with vortioxetine were conflicting, with one trial being positive” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In a RCT, trazodone was as effective as diazepam (Level 2)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
BAP guideline: tricyclic antidepressants, agomelatine, and mirtazapine
Network meta-analysis: mirtazapine and agomelatine
Imipramine and trazodone compared with diazepam
“In this study response rates were 73% for imipramine-treated patients, compared to 69% for patients receiving trazodone and 66% for those receiving diazepam, and 47% for the placebo group.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“While the use of TCAs has largely been supplanted by the use of SSRIs for the treatment of GAD, they still represent a viable option for patients who fail to respond after multiple trials of SSRIs, SNRIs, and adjunctive psychopharmacologic interventions.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote